The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing outcome differences in the second line treatment of metastatic colorectal cancer (mCRC): An ARCAD analysis comparing sequence after first line trials (SAFL) and dedicated second line trials (DSLT).
 
Alexis Diane Leal
No Relationships to Disclose
 
Fang-Shu Ou
No Relationships to Disclose
 
Levi Pederson
No Relationships to Disclose
 
Alberto F. Sobrero
No Relationships to Disclose
 
Mace L. Rothenberg
No Relationships to Disclose
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
 
Marc Peeters
No Relationships to Disclose
 
Henry C. Pitot
No Relationships to Disclose
 
Cornelis J. A. Punt
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Nordic Bioscience; Roche
 
Dirk Arnold
Honoraria - Bayer; Merck Serono; Roche/Genentech; SERVIER; TERUMO
Consulting or Advisory Role - Bayer; Biocompatibles; Helsinn Therapeutics; Merck Serono; Roche; Servier; Terumo
Research Funding - Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche/Genentech
 
Bruce J. Giantonio
No Relationships to Disclose
 
Christophe Tournigand
Honoraria - Bayer; Lilly; Roche; Sanofi
Consulting or Advisory Role - Lilly; Sandoz
Research Funding - Roche
Travel, Accommodations, Expenses - Bayer; Pfizer; Roche; Sanofi
 
Shaheenah Dawood
No Relationships to Disclose
 
Aimery De Gramont
No Relationships to Disclose
 
Daniel J. Sargent
Consulting or Advisory Role - Abbvie; Acerta Pharma; ARIAD; Astellas Pharma; AstraZeneca/MedImmune; Biothera; Celldex; Exelixis; Genentech; Incyte; Kyowa Hakko Kirin; Medivation; Merck; Merrimack; Nektar; Novartis; Pharmacyclics; Pique; Spiration; Xbiotech
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene
 
Axel Grothey
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche